Results 231 to 240 of about 11,332,305 (264)

Validation of an MRI Rating Scale for Amyloid-Related Imaging Abnormalities [PDF]

Journal of Neuroimaging, 2017
INTRODUCTION: Immunotherapeutic agents against amyloid beta (Aβ) are associated with adverse events, including amyloid-related imaging abnormalities with edema and effusion (ARIA-E). Recently, a magnetic resonance imaging (MRI) rating scale was developed
Mike P. Wattjes, Marita Daams, Frederik Barkhof   +2 more
exaly   +6 more sources

Some of the next articles are maybe not open access.

Related searches:

Amyloid-Related Imaging Abnormalities: An Update

American Journal of Roentgenology, 2023
Amyloid-related imaging abnormalities (ARIA) is a term introduced in 2010 to encompass a spectrum of MRI findings observed in patients receiving investigational anti-amyloid beta (Aβ) immunotherapies for Alzheimer disease (AD). The entity can be broadly categorized into ARIA characterized by edema and effusion (ARIA-E) and ARIA characterized by ...
Michelle Roytman, Greg Zaharchuk
exaly   +3 more sources

Imaging of Amyloid-Related Imaging Abnormalities (ARIA)

RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, 2023
Patients with Alzheimer’s disease (AD) can now be treated with monoclonal antibodies aiming at clearing amyloid plaques from the brain parenchyma. Weeks after initiation of this drug therapy, patients may develop so-called amyloid-related imaging abnormalities (ARIA) on MRI. ARIA comprise vasogenic edema and leptomeningeal effusions (ARIA-E) as well as
Horst Urbach, Jennifer Linn, Elke Hattingen, Jochen Fiebach   +3 more
openaire   +2 more sources

Amyloid-Related Imaging Abnormalities From Trials of Solanezumab for Alzheimer's Disease

Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016
AbstractIntroductionSolanezumab, a humanized monoclonal antibody that binds soluble amyloid beta peptide, is being developed for treatment of Alzheimer's disease (AD).MethodsPatients (n = 2042) with mild and moderate AD were randomized 1:1 to 400‐mg solanezumab or placebo infusion every 4 weeks for 80 weeks and 1457 patients entered an open‐label ...
Ann Marie Hake, Jerome Barakos, Michael Case   +2 more
exaly   +3 more sources

Altered Clearance and Amyloid-Related Imaging Abnormalities

Neuroimaging Clinics of North America
Amyloid-related imaging abnormalities (ARIA) are parenchymal edema/effusion and hemorrhage that occur as side effects of immunotherapies targeting beta-amyloid for patients with Alzheimer's disease (AD). The mechanism of ARIA remains unclear but is thought to be due to loss of vascular integrity secondary to overwhelming perivascular clearance pathways,
Brian J Burkett, Derek R. Johnson, Petrice M Cogswell   +2 more
exaly   +3 more sources

Amyloid-Related Imaging Abnormalities and β-Amyloid–Targeting Antibodies

JAMA Neurology, 2022
After more than a decade of research and development of clinical trials testing anti-β-amyloid monoclonal antibodies (mAbs), extensive experience has been gained regarding the effects of these treatments in patients with Alzheimer disease (AD). On the verge of an expected large-scale introduction in the clinical setting after the recent US Food and ...
Filippi M., Cecchetti G., Spinelli E. G., Vezzulli P., Falini A., Agosta F.   +5 more
openaire   +2 more sources

Amyloid-Related Imaging Abnormalities in Patients With Alzheimer's Disease Treated With Bapineuzumab: A Retrospective Analysis [PDF]

Lancet Neurology, The, 2012
Amyloid-related imaging abnormalities (ARIA) have been reported in patients with Alzheimer's disease treated with bapineuzumab, a humanised monoclonal antibody against amyloid β. ARIA include MRI signal abnormalities suggestive of vasogenic oedema and sulcal effusions (ARIA-E) and microhaemorrhages and haemosiderin deposits (ARIA-H).
Anton P. Porsteinsson, Stephen Salloway, Nick C. Fox   +2 more
exaly   +4 more sources

Amyloid-Related Imaging Abnormalities in AβPP Duplication Carriers

Journal of Alzheimer’s Disease, 2013
Immune response to vascular amyloid-β deposits leads to cerebral amyloid angiopathy related-inflammation (CAA-ri). Amyloid-related imaging abnormalities (ARIA) were initially reported during anti-amyloid trials and are associated with the APOE 4/4 genotype. We report the evolution of an AβPP duplication carrier with an APOE 3/3 genotype presenting ARIA-
Ludivine, Chamard, David, Wallon, Alexa, Pijoff, Eric, Berger, Gabriel, Viennet, Didier, Hannequin, Eloi, Magnin   +6 more
openaire   +2 more sources

Amyloid related imaging abnormalities in the emergency setting

Emergency Radiology
Since the 2021 FDA approval of the first monoclonal antibody (MAB) therapy for Alzheimer's disease (AD), treatment has progressed from symptom management to targeting and reducing amyloid β plaque burden. While these therapies offer hope of altering the disease course, they come with risks, such as amyloid-related imaging abnormalities (ARIA), which ...
Jan Czerminski, Supriya Khatri, Balaji Rao   +2 more
openaire   +2 more sources

Amyloid-Related Imaging Abnormalities in an Aged Squirrel Monkey with Cerebral Amyloid Angiopathy [PDF]

Journal of Alzheimer's Disease, 2017
Amyloid-related imaging abnormalities (ARIA) in magnetic resonance imaging scans have emerged as indicators of potentially serious side effects in clinical trials of therapeutics for Alzheimer’s disease. These anomalies include an edematous type (ARIA-E) that appears as hyperintense (bright) regions by T2-weighted MRI, and a type characterized by the ...
Eric, Heuer, Jessica, Jacobs, Rebecca, Du, Silun, Wang, Orion P, Keifer, Amarallys F, Cintron, Jeromy, Dooyema, Yuguang, Meng, Xiaodong, Zhang, Lary C, Walker   +9 more
openaire   +2 more sources